Floatz logo

egf816

Neoplasms by Histologic Type

Cancer Research UKSmall moleculePhase 2/3Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Neoplasms by Histologic Type cohort.

Asset / SponsorPhaseRating
Benadryl
Hellenic Society of Hematology
Phase 2B
Capmatinib
Cancer Research UK
Phase 2/3CCC
GEMOGENOVATUCEL-T
Gradalis, Inc.
Phase 3CCC
Penpulimab
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC
Isatuximab
Hellenic Society of Hematology
Phase 2CCC

View all 17 →

Same molecule, other indications

egf816 is also rated in:

Carcinoma, Non-Small-Cell LungDormant
CCC
Indicative ·
52 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →